Search

Your search keyword '"Zangaglia, R."' showing total 200 results
Start Over Author "Zangaglia, R."
200 results on '"Zangaglia, R."'

1. Gender differences in microRNA expression in levodopa-naive PD patients

Author

Vallelunga, A., Iannitti, T., Somma, G., Russillo, M. C., Picillo, M., De Micco, R., Vacca, L., Cilia, R., Cicero, C. E., Zangaglia, R., Lazzeri, G., Galantucci, S., Radicati, F. G., De Rosa, A., Amboni, M., Scaglione, C., Tessitore, A., Stocchi, F., Eleopra, R., Nicoletti, A., Pacchetti, C., Di Fonzo, A., Volontè, M. A., Barone, P., and Pellecchia, M. T.

Published
2023
Full Text
View/download PDF

2. Interaction between sex and GBA mutations influences clinical phenotype in Parkinson disease

Author

Gallo, L., primary, Avenali, M., additional, Caminiti, S., additional, Mitrotti, P., additional, Pocora, M., additional, Cuconato, G., additional, Palmieri, I., additional, Pasquini, C., additional, Galandra, C., additional, Calabrese, R., additional, Zangaglia, R., additional, Tassorelli, C., additional, Schapira, A.V.H., additional, Valente, E.M., additional, and Blandini, F., additional

Published
2024
Full Text
View/download PDF

4. Does Deep Brain Stimulation worsen cognitive decline in GBA-Parkinson Disease patients? A longitudinal study of the Italian PARKNET cohort

Author

AVENALI, M., primary, Artusi, C.A., additional, Cilia, R., additional, Giannini, G., additional, Cuconato, G., additional, Pasquini, C., additional, Albanese, A., additional, Antonini, A., additional, Bentivoglio, A.R., additional, Bove, F., additional, Bozzali, M., additional, Calandra-Buonaura, G., additional, Carelli, V., additional, Francesco, C., additional, Cocco, A., additional, Cogiamanian, F., additional, Colucci, F., additional, Cortelli, P., additional, Di Fonzo, A., additional, D'Onofrio, V., additional, Eleopra, R., additional, Elia, A.E., additional, Fioravanti, V., additional, Golfrè Andreasi, N., additional, Guerra, A., additional, Ledda, C., additional, Liccari, M., additional, Longo, C., additional, Lopiano, L., additional, Malaguti, M., additional, Mameli, F., additional, Minardi, R., additional, Monfrini, E., additional, Pacchetti, C., additional, Piano, C., additional, Rizzone, M., additional, Romito, L., additional, Sambati, L., additional, Spagnolo, F., additional, Tassorelli, C., additional, Valentino, F., additional, Valzania, F., additional, Zangaglia, R., additional, Zibetti, M., additional, and Valente, E.M., additional

Published
2024
Full Text
View/download PDF

7. Correction to: Gender differences in microRNA expression in levodopa‑naive PD patients

Author

Vallelunga, A., Iannitti, T., Somma, G., Russillo, M. C., Picillo, M., De Micco, R., Vacca, L., Cilia, R., Cicero, C. E., Zangaglia, R., Lazzeri, G., Galantucci, S., Radicati, F. G., De Rosa, A., Amboni, M., Scaglione, C., Tessitore, A., Stocchi, F., Eleopra, R., Nicoletti, A., Pacchetti, C., Di Fonzo, A., Volontè, M. A., Barone, P., and Pellecchia, M. T.

Published
2023
Full Text
View/download PDF

9. Consensus on the treatment of dysphagia in Parkinson's disease

Author

Schindler, A., Pizzorni, N., Cereda, E., Cosentino, G., Avenali, M., Montomoli, C., Abbruzzese, G., Antonini, A., Barbiera, F., Benazzo, M., Benarroch, E., Bertino, G., Clave, P., Cortelli, P., Eleopra, R., Ferrari, C., Hamdy, S., Huckabee, M. -L., Lopiano, L., Marchese-Ragona, R., Masiero, S., Michou, E., Occhini, A., Pacchetti, C., Pfeiffer, R. F., Restivo, D. A., Rondanelli, M., Ruoppolo, G., Sandrini, G., Schapira, A., Stocchi, F., Tolosa, E., Valentino, F., Zamboni, M., Zangaglia, R., Zappia, M., Tassorelli, C., Alfonsi, E., Schindler A., Pizzorni N., Cereda E., Cosentino G., Avenali M., Montomoli C., Abbruzzese G., Antonini A., Barbiera F., Benazzo M., Benarroch E., Bertino G., Clave P., Cortelli P., Eleopra R., Ferrari C., Hamdy S., Huckabee M.-L., Lopiano L., Marchese-Ragona R., Masiero S., Michou E., Occhini A., Pacchetti C., Pfeiffer R.F., Restivo D.A., Rondanelli M., Ruoppolo G., Sandrini G., Schapira A., Stocchi F., Tolosa E., Valentino F., Zamboni M., Zangaglia R., Zappia M., Tassorelli C., and Alfonsi E.

Subjects
Consensus, Parkinson's disease, Clinical Neurology, Consensu, Consensus development conference, Deglutition disorders, Nutrition, Rehabilitation, Humans, Italy, Deglutition Disorders, Parkinson Disease, QUALITY-OF-LIFE, INTENSIVE VOICE TREATMENT, otorhinolaryngologic diseases, Deglutition Disorder, NEUROMUSCULAR ELECTRICAL-STIMULATION, Science & Technology, SUBTHALAMIC NUCLEUS, ESPEN GUIDELINES, Neurosciences, PULMONARY-FUNCTION, TREATMENT LSVT(R), OROPHARYNGEAL DYSPHAGIA, SWALLOWING DISORDERS, Neurosciences & Neurology, DEEP-BRAIN-STIMULATION, Life Sciences & Biomedicine, Human
Abstract

BACKGROUND: Dysphagia is common in Parkinson's disease (PD). The effects of antiparkinsonian drugs on dysphagia are controversial. Several treatments for dysphagia are available but there is no consensus on their efficacy in PD. OBJECTIVE: To conduct a systematic review of the literature and to define consensus statements on the treatment of dysphagia in PD and related nutritional management. METHODS: A multinational group of experts in the field of neurogenic dysphagia and/or Parkinson's disease conducted a systematic evaluation of the literature and reported the results according to PRISMA guidelines. The evidence from the retrieved studies was analyzed and discussed in a consensus conference organized in Pavia, Italy, and the consensus statements were drafted. The final version of statements was subsequently achieved by e-mail consensus. RESULTS: The literature review retrieved 64 papers on treatment and nutrition of patients with PD and dysphagia, mainly of Class IV quality. Based on the literature and expert opinion in cases where the evidence was limited or lacking, 26 statements were developed. CONCLUSIONS: The statements developed by the Consensus panel provide a guidance for a multi-disciplinary treatment of dysphagia in patients with PD, involving neurologists, otorhinolaryngologists, gastroenterologists, phoniatricians, speech-language pathologists, dieticians, and clinical nutritionists. ispartof: JOURNAL OF THE NEUROLOGICAL SCIENCES vol:430 ispartof: location:Netherlands status: published

Published
2021

11. GBA-Related Parkinson’s Disease:Dissection of Genotype–Phenotype Correlates in a LargeItalian Cohort

Author

Petrucci, S., Ginevrino, M., Trezzi, I., Monfrini, E., Ricciardi, L., Albanese, A., Avenali, M., Barone, P., Bentivoglio, A. R., Bonifati, V., Bove, F., Bonanni, L., Brusa, L., Cereda, C., Cossu, G., Criscuolo, C., Dati, G., De Rosa, A., Eleopra, R., Fabbrini, G., Fadda, L., Garbellini, M., Minafra, B., Onofrj, M., Pacchetti, C., Palmieri, I., Pellecchia, M. T., Petracca, M., Picillo, M., Pisani, A., Vallelunga, A., Zangaglia, R., Di Fonzo, A., Morgante, F., Valente, E. M., Altavista, M. C., Amboni, M., Ardolino, G., Berardelli, A., Cogiamanian, F., Colosimo, C., Costanti, D., De Michele, G., Bonaventura, C. D., Di Lazzaro, G., Di Lazzaro, V., Emanuele Elia, A., Erro, R., Ferrazzano, G., Guerra, A., Ialongo, T., Malaguti, M. C., Melis, M., Moro, E., Oppo, V., Ottaviani, D., Peluso, S., Quadri, M. L., Romito, L. M., Sarchioto, M., Schirinzi, T., Sorbera, C., Stefani, A., Thomas, A., Valente, M. L., Volpe, G, ITA-GENE-PD Study, Group., Petrucci, S, Ginevrino, M, Trezzi, I, Monfrini, E, Ricciardi, L, Albanese, A, Avenali, M, Barone, P, Bentivoglio, Ar, Bonifati, V, Bove, F, Bonanni, L, Brusa, L, Cereda, C, Cossu, G, Criscuolo, C, Dati, G, De Rosa, A, Eleopra, R, Fabbrini, G, Fadda, L, Garbellini, M, Minafra, B, Onofrj, M, Pacchetti, C, Palmieri, I, Pellecchia, Mt, Petracca, M, Picillo, M, Pisani, A, Vallelunga, A, Zangaglia, R, Di Fonzo, A, Morgante, F, Valente, Em, Clinical Genetics, Erasmus MC other, and Radiology & Nuclear Medicine

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Parkinson's disease, Genotype, genotype–phenotype correlates, Disease, Settore MED/05, Genotype phenotype, dementia, GBA, impulsive–compulsive behavior, 03 medical and health sciences, symbols.namesake, 0302 clinical medicine, Internal medicine, medicine, Dementia, Humans, Sanger sequencing, business.industry, Dissection, Parkinson Disease, medicine.disease, Phenotype, Settore MED/26 - NEUROLOGIA, 030104 developmental biology, Glucosylceramidase, Italy, Mutation, Neurology, Cohort, symbols, Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract

BACKGROUND Variants in GBA are the most common genetic risk factor for Parkinson's disease (PD). The impact of different variants on the PD clinical spectrum is still unclear. OBJECTIVES We determined the frequency of GBA-related PD in Italy and correlated GBA variants with motor and nonmotor features and their occurrence over time. METHODS Sanger sequencing of the whole GBA gene was performed. Variants were classified as mild, severe, complex, and risk. β-glucocerebrosidase activity was measured. The Kaplan-Meier method and Cox proportional hazard regression models were performed. RESULTS Among 874 patients with PD, 36 variants were detected in 14.3%, including 20.4% early onset. Patients with GBA-PD had earlier and more frequent occurrence of several nonmotor symptoms. Patients with severe and complex GBA-PD had the highest burden of symptoms and a higher risk of hallucinations and cognitive impairment. Complex GBA-PD had the lowest β-glucocerebrosidase activity. CONCLUSIONS GBA-PD is highly prevalent in Italy. Different types of mutations underlie distinct phenotypic profiles. © 2020 International Parkinson and Movement Disorder Society.

Published
2020

13. GBA-Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort

Author

Petrucci, S., Ginevrino, M., Trezzi, I., Monfrini, E., Ricciardi, L., Albanese, A., Avenali, M., Barone, P., Bentivoglio, A. R., Bonifati, V., Bove, F., Bonanni, L., Brusa, L., Cereda, C., Cossu, G., Criscuolo, C., Dati, G., De Rosa, A., Eleopra, R., Fabbrini, G., Fadda, L., Garbellini, M., Minafra, B., Onofrj, M., Pacchetti, C., Palmieri, I., Pellecchia, M. T., Petracca, M., Picillo, M., Pisani, A., Vallelunga, A., Zangaglia, R., Di Fonzo, A., Morgante, F., and Valente, E. M.

Subjects
dementia, GBA, genotype–phenotype correlates, impulsive–compulsive behavior, Parkinson's disease
Published
2020

20. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study

Author

Lopiano, L, Modugno, N, Marano, P, Sensi, M, Meco, G, Solla, P, Gusmaroli, G, Tamma, F, Mancini, Federico, Quatrale, R, Zangaglia, R, Bentivoglio, Anna Rita, Eleopra, R, Gualberti, G, Melzi, G, Antonini, A, Mancini, F, Bentivoglio, A (ORCID:0000-0002-9663-095X), Lopiano, L, Modugno, N, Marano, P, Sensi, M, Meco, G, Solla, P, Gusmaroli, G, Tamma, F, Mancini, Federico, Quatrale, R, Zangaglia, R, Bentivoglio, Anna Rita, Eleopra, R, Gualberti, G, Melzi, G, Antonini, A, Mancini, F, and Bentivoglio, A (ORCID:0000-0002-9663-095X)

Abstract

Introduction The GREENFIELD observational study assessed the effect of levodopa/carbidopa intestinal gel (LCIG) on motor and non-motor symptoms, and the related impact on patient quality of life and caregiver burden up to 8 years. Methods Final results of a large Italian cohort of patients who started LCIG in routine care between 2007 and 2014 are presented. Comparison between baseline (before LCIG) and follow-up visits on yearly basis (visit 2/3) is reported. Primary endpoint was Unified Parkinson's Disease Rating Scale (UPDRS-IV) Item 39; secondary endpoints were UPDRS I and II, dyskinesia items, PD Quality of Life Questionnaire-39, Parkinson's Disease Sleep Scale-2, Gait and Falls Questionnaire, Questionnaire on Impulsive Disorders, and Relative Stress Scale. Results Overall, 145 patients from 14 centers were assessed with a mean time since LCIG start of 2.8 +/- 1.7 years at visit 2. The mean UPDRS-IV item 39 score showed significant reductions compared to baseline (mean score 2.0 +/- 0.81) at visit 2 (mean score 0.9 +/- 0.69; - 55%; p < 0.001) and at visit 3 (mean score 1.0 +/- 0.75; - 50%; p < 0.001). At visit 3, significant reductions were observed for dyskinesia duration score (- 28%; p < 0.001), dyskinesia disability (- 40%; p < 0.001), and painful dyskinesia (- 50%; p < 0.001). Overall, 40 (27.6%) patients experienced 49 serious adverse events which were considered related to PEG/J procedure or to device in 16.3% of the cases. Conclusions The results of this study support the long-term efficacy of LCIG on PD symptoms as well as on activities of daily living. The adverse events were consistent with the established LCIG safety profile.

Published
2019

25. Subthalamic local field potentials after seven-year deep brain stimulation in Parkinson's disease

Author

Giannicola, G, Rosa, M, Servello, D, Menghetti, C, Carrabba, G, Pacchetti, C, Zangaglia, R, Cogiamanian, F, Scelzo, E, Marceglia, S, Rossi, L, Priori, A, Giannicola G, Rosa M, Servello D, Menghetti C, Carrabba G, Pacchetti C, Zangaglia R, Cogiamanian F, Scelzo E, Marceglia S, Rossi L, Priori A, Giannicola, G, Rosa, M, Servello, D, Menghetti, C, Carrabba, G, Pacchetti, C, Zangaglia, R, Cogiamanian, F, Scelzo, E, Marceglia, S, Rossi, L, Priori, A, Giannicola G, Rosa M, Servello D, Menghetti C, Carrabba G, Pacchetti C, Zangaglia R, Cogiamanian F, Scelzo E, Marceglia S, Rossi L, and Priori A

Abstract

Studies describing subthalamic (STN) local field potentials (LFPs) recorded during deep brain stimulation (DBS) in patients with Parkinson's disease (PD), within the first month after DBS electrode implant, show that DBS modulates specific STN oscillations: whereas low-frequency (LF) oscillations (2-7Hz) increase, beta oscillations (8-30 Hz) variably decrease. No data show whether LFPs remain stable for longer than one month after DBS surgery. Having long-term information is essential especially for use as a long-term feedback control signal for adaptive DBS systems. To evaluate how STN activity behaves years after prolonged chronic stimulation in PD we studied STN LFPs at rest without DBS and during ongoing DBS, in 11 parkinsonian patients 7 years (7.54 +/- 1.04) after STN electrode implantation for DBS (hyperchronic group) and in 16 patients 3 days after STN electrode implantation (acute group). STN LF and beta-band LFPs recorded at rest at 7 years contained almost the same information as those recorded at 3 days. STN recordings showed similar LFP responses to DBS in the acute and hyperchronic stages: whereas during ongoing DBS the LF power band increased for the whole population, beta activity decreased only in nuclei with significant beta activity at baseline. The LF/beta power ratio in all nuclei changed in both study groups, suggesting that this variable might be an even more informative marker of PD than the single LF and beta bands. Because STN LFP activity patterns and STN LFP responses to DBS stay almost unchanged for years after DBS electrode implantation they should provide a consistent feedback control signal for adaptive DBS. (c) 2012 Elsevier Inc. All rights reserved.

Published
2012

26. Validation of the Italian version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Author

Antonini, A, Abbruzzese, G, Ferini Strambi, L, Tilley, B, Huang, J, Stebbins, Gt, Goetz, Cg, Barone, P, MDS UPDRS Italian Validation Study Group, Bandettini di Poggio, M, Fabbrini, G, Di Stasio, F, Tinazzi, M, Bovi, T, Ramat, S, Meoni, S, Pezzoli, G, Canesi, M, Martinelli, P, Maria Scaglione CL, Rossi, A, Tambasco, N, Santangelo, G, Picillo, M, Morgante, Letterio, Morgante, Francesca, Quatrale, R, Sensi, M, Pilleri, M, Biundo, R, Nordera, G, Caria, A, Pacchetti, C, Zangaglia, R, Lopiano, L, Zibetti, M, Zappia, M, Nicoletti, A, Quattrone, A, Salsone, M, Cossu, G, Murgia, D, Albanese, A, Del Sorbo, F., Antonini, A, Abbruzzese, G, Ferini Strambi, L, Tilley, B, Huang, J, Stebbins, Gt, Goetz, Cg, Barone, P, MDS UPDRS Italian Validation Study, Group, Bandettini di Poggio, M, Fabbrini, G, Di Stasio, F, Tinazzi, M, Bovi, T, Ramat, S, Meoni, S, Pezzoli, G, Canesi, M, Martinelli, P, Maria Scaglione, Cl, Rossi, A, Tambasco, N, Santangelo, Gabriella, Picillo, M, Morgante, L, Morgante, F, Quatrale, R, Sensi, M, Pilleri, M, Biundo, R, Nordera, G, Caria, A, Pacchetti, C, Zangaglia, R, Lopiano, L, Zibetti, M, Zappia, M, Nicoletti, A, Quattrone, A, Salsone, M, Cossu, G, Murgia, D, Albanese, A, and Del Sorbo, F.

Subjects
Male, Unified Parkinson's Disease Rating Scale, Mds updrs, Parkinson's disease, Unified Parkinson’s Disease Rating Scale, Unified Parkinson's disease rating scale, Dermatology, Neuropsychological Tests, Factor structure, Severity of Illness Index, MDS-UPDRS, rating scale, rating scales, Disability Evaluation, Rating scale, Medical, Humans, Translations, Societies, Medical, Neurologic Examination, Protocol (science), Movement Disorders, Movement (music), Reproducibility of Results, Parkinson Disease, General Medicine, Statistical, Linguistics, Focus (linguistics), Settore MED/26 - NEUROLOGIA, Psychiatry and Mental health, Italy, Index (publishing), Female, Neurology (clinical), Societies, Factor Analysis, Statistical, Psychology, Factor Analysis, Social psychology
Abstract

The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) has been available in English since 2008. As part of this process, the MDS-UPDRS organizing team developed guidelines for development of official non- English translations. We present here the formal process for completing officially approved non-English versions of the MDS-UPDRS and specifically focus on the first of these versions in Italian. The MDS-UPDRS was translated into Italian and tested in 377 native-Italian speaking PD patients. Confirmatory and exploratory factor analyses determined whether the factor structure for the English- language MDS-UPDRS could be confirmed in data col- lected using the Italian translation. To be designated an 'Official MDS translation,' the Comparative Fit Index (CFI) had to be C0.90 relative to the English-language version. For all four parts of the Italian MDS-UPDRS, the CFI, in comparison with the English-language data, was C0.94. Exploratory factor analyses revealed some differ- ences between the two datasets, however these differences were considered to be within an acceptable range. The Italian version of the MDS-UPDRS reaches the criterion to be designated as an Official Translation and is now avail- able for use. This protocol will serve as outline for further validation of this in multiple languages.

Published
2013

27. Cognitive disorders in normal pressure hydrocephalus with initial parkinsonism in comparison with de novo Parkinson's disease.

Author

Picascia, M., Pozzi, N. G., Todisco, M., Minafra, B., Sinforiani, E., Zangaglia, R., Ceravolo, R., and Pacchetti, C.

Subjects
PARKINSON'S disease, MOVEMENT disorders, COGNITION disorders, PARKINSON'S disease diagnosis, NEUROPSYCHOLOGICAL tests
Abstract

Background and purpose: The clinical differentiation between parkinsonism in idiopathic normal pressure hydrocephalus (iNPH) and Parkinson's disease (PD) remains challenging in the initial phase. Whether an early cognitive profiling might support the differential diagnosis of early iNPH and PD was addressed. Methods: Neuropsychological tests of 40 iNPH subjects with early symptoms resembling parkinsonism were retrospectively evaluated together with 47 de novoPD patients (dnPD). Only neuropsychological tests performed within 1 year from the first motor symptom were included. The cognitive spectrum of iNPH and dnPD was also compared with a sample of 70 normal controls. Results: A clear difference in the cognitive profile of iNPH, dnPD patients and normal controls was shown. 65% of iNPH subjects showed a diffuse cognitive impairment, including memory, visuospatial abilities, fronto‐executive functioning and attention, whereas only 25.5% of the dnPD patients presented an executive dysfunction. 35% of iNPH and 74.5% of PD patients performed within the normal range (P < 0.05). Conclusion: Subjects with iNPH showed an early and diffuse alteration of cognition with respect to dnPD patients. Performing a prompt and accurate neuropsychological evaluation might support the differential diagnosis of these two conditions of parkinsonism. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

28. Validation of the Italian version of Parkinson's disease-cognitive rating scale (PD-CRS)

Author

Santangelo, G., Barone, P., Abbruzzese, G., Ferini Strambi, L., Antonini, A, Bandettini, M., Fabbrini, G., Di Stasio, F., Tinazzi, M., Bovi, T., Ramat, S., Meoni, S., Pezzoli, G., Siri, C., Canesi, M., Martinelli, P., Scaglione, C. L., Rossi, A., Tambasco, N., Picillo, M., Morgante, Letterio, Morgante, Francesca, Quatrale, R., Sensi, M. C., Pilleri, M., Biundo, R., Nordera, G., Caria, A., Pacchetti, C., Zangaglia, R., Lopiano, L., Zibetti, M., Morgante, L., Morgante, F., Zappia, M., Nicoletti, A., Quattrone, A., Salsone, M., Cossu, G., Murgia, D., Albanese, A., Del Sorbo, F., Santangelo, Gabriella, Barone, Paolo, Abbruzzese, Giovanni, Ferini-strambi, Luigi, and Antonini, Angelo

Subjects
Male, medicine.medical_specialty, Parkinson's disease, Neurology, Dermatology, Audiology, Neuropsychological Tests, Cognition Disorder, Cognitive dysfunction, Rating scale, medicine, Dementia, Humans, Cognitive dysfunctions, Mild cognitive impairment, Parkinson's Disease Cognitive Rating Scale (PD-CRS), Aged, Cognition Disorders, Female, Italy, Middle Aged, Parkinson Disease, Neurology (clinical), Psychiatry and Mental Health, 2708, Psychiatry, Working memory, Cognition, General Medicine, medicine.disease, Confidence interval, Psychiatry and Mental health, Ceiling effect, Neuropsychological Test, Psychology, Human
Abstract

Cognitive impairment (CI) is a frequent feature associated with both early and advanced stages of Parkinson's disease (PD). An evaluation of cognitive functions is relevant to identify those parkinsonians at risk of developing dementia. In the present study, the Italian version of Parkinson's Disease-Cognitive Rating Scale (PD-CRS) assessing fronto-subcortical and cortical cognitive functions in PD was validated in 387 parkinsonians and was used to test the empirical validity of the item 1.1 (cognitive impairment) of the Italian version of MDS-UPDRS as screening tool for CI in PD. PD-CRS was free from floor and ceiling effect. The mean PD-CRS score was 76.1 (mean cortical score, 24.5 ± 4.6; mean subcortical score, 51.5 ± 17.5). The internal consistency was satisfactory (α = 0.89); corrected item-total correlation was 0.570 (naming) to 0.696 (working memory). The correlation between PD-CRS and part I-IV of MDS-UPDRS was weak. The low agreement between classification of PD sample into patients with mild cognitive impairment (PD-MCI), dementia (PD-D) and normal cognition (PD-NC) according to scores of item 1.1 and classification according to cutoff scores of PD-CRS for PD-MCI, PD-D and PD-NC indicated a poor empirical validity of item 1.1 of MDS-UPDRS as cognitive screening tool for CI in PD (Κ = 0.114; weighted Κ = 0.17; SE of Κ = 0.038; 95 % confidence interval from 0.040 to 0.1895). The Italian version of PD-CRS is an easy, consistent and valid tool for assessment of the cognitive cortical and subcortical impairments in PD. © 2013 Springer-Verlag.

Published
2013

31. Caratteristiche Cliniche

Author

Amboni, M, Berardelli, A, Ceravolo, R, Colosimo, C, Glorioso, M, Guidi, M, Manni, R, Marconi, R, Ottaviani, D, Pacchetti, C, Pellecchia, Mt, Pellicano, C, Pierantozzi, M, Pontieri, F, Stanzione, P, and Zangaglia, R

Published
2008

39. Validation of the Italian version of the Movement Disorder Society - Unified Parkinson's Disease Rating Scale

Author

Antonini, A., Abbruzzese, G., Ferini-Strambi, L., Tilley, B., Huang, J., Stebbins, G. T., Goetz, C. G., Barone, P., Bandettini Di Poggio, M., Fabbrini, G., Di Stasio, F., Tinazzi, M., Bovi, T., Ramat, S., Meoni, S., Pezzoli, G., Canesi, M., Martinelli, P., Maria Scaglione, C. L., Rossi, A., Tambasco, N., Santangelo, G., Picillo, M., Morgante, L., Morgante, F., Quatrale, R., Sensi, M., Pilleri, M., Biundo, R., Nordera, G., Caria, A., Pacchetti, C., Zangaglia, R., Lopiano, L., Zibetti, M., Zappia, M., Nicoletti, A., Quattrone, A., Salsone, M., Cossu, G., Murgia, D., Albanese, Alberto, Del Sorbo, F., Albanese A. (ORCID:0000-0002-5864-0006), Antonini, A., Abbruzzese, G., Ferini-Strambi, L., Tilley, B., Huang, J., Stebbins, G. T., Goetz, C. G., Barone, P., Bandettini Di Poggio, M., Fabbrini, G., Di Stasio, F., Tinazzi, M., Bovi, T., Ramat, S., Meoni, S., Pezzoli, G., Canesi, M., Martinelli, P., Maria Scaglione, C. L., Rossi, A., Tambasco, N., Santangelo, G., Picillo, M., Morgante, L., Morgante, F., Quatrale, R., Sensi, M., Pilleri, M., Biundo, R., Nordera, G., Caria, A., Pacchetti, C., Zangaglia, R., Lopiano, L., Zibetti, M., Zappia, M., Nicoletti, A., Quattrone, A., Salsone, M., Cossu, G., Murgia, D., Albanese, Alberto, Del Sorbo, F., and Albanese A. (ORCID:0000-0002-5864-0006)

Abstract

The Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) has been available in English since 2008. As part of this process, the MDS-UPDRS organizing team developed guidelines for development of official non-English translations. We present here the formal process for completing officially approved non-English versions of the MDS-UPDRS and specifically focus on the first of these versions in Italian. The MDS-UPDRS was translated into Italian and tested in 377 native-Italian speaking PD patients. Confirmatory and exploratory factor analyses determined whether the factor structure for the English-language MDS-UPDRS could be confirmed in data collected using the Italian translation. To be designated an 'Official MDS translation,' the Comparative Fit Index (CFI) had to be ≥0.90 relative to the English-language version. For all four parts of the Italian MDS-UPDRS, the CFI, in comparison with the English-language data, was ≥0.94. Exploratory factor analyses revealed some differences between the two datasets, however these differences were considered to be within an acceptable range. The Italian version of the MDS-UPDRS reaches the criterion to be designated as an Official Translation and is now available for use. This protocol will serve as outline for further validation of this in multiple languages. © 2012 Springer-Verlag.

Published
2013

42. Conflict-dependent dynamic of subthalamic nucleus oscillations during moral decisions

Author

Fumagalli, M., Giannicola, G., Rosa, M., Marceglia, S., Lucchiari, C., Mrakic-Sposta, S., Servello, D., Pacchetti, C., Porta, M., Sassi, M., Zangaglia, R., Franzini, A., Albanese, Alberto, Romito, Luigi Michele Antonio, Piacentini, S., Zago, S., Pravettoni, G., Barbieri, S., Priori, A., Albanese A. (ORCID:0000-0002-5864-0006), Romito L., Fumagalli, M., Giannicola, G., Rosa, M., Marceglia, S., Lucchiari, C., Mrakic-Sposta, S., Servello, D., Pacchetti, C., Porta, M., Sassi, M., Zangaglia, R., Franzini, A., Albanese, Alberto, Romito, Luigi Michele Antonio, Piacentini, S., Zago, S., Pravettoni, G., Barbieri, S., Priori, A., Albanese A. (ORCID:0000-0002-5864-0006), and Romito L.

Abstract

Although lesional, neuroimaging, and brain stimulation studies have provided an insight into the neural mechanisms of judgement and decision-making, all these works focused on the cerebral cortex, without investigating the role of subcortical structures such as the basal ganglia. Besides being an effective therapeutic tool, deep brain stimulation (DBS) allows local field potential (LFP) recordings through the stimulation electrodes thus providing a physiological "window" on human subcortical structures. In this study we assessed whether subthalamic nucleus LFP oscillations are modulated by processing of moral conflictual, moral nonconflictual, and neutral statements. To do so, in 16 patients with Parkinson's disease (8 men) bilaterally implanted with subthalamic nucleus (STN) electrodes for DBS, we recorded STN LFPs 4 days after surgery during a moral decision task. During the task, recordings from the STN showed changes in LFP oscillations. Whereas the 14-30 Hz band (beta) changed during the movement executed to perform the task, the 5-13 Hz band (low-frequency) changed when subjects evaluated the content of statements. Low-frequency band power increased significantly more during conflictual than during nonconflictual or neutral sentences. We conclude that STN responds specifically to conflictual moral stimuli, and could be involved in conflictual decisions of all kinds, not only those for moral judgment. LFP oscillations provide novel direct evidence that the neural processing of conflictual decision-making spreads beyond the cortex to the basal ganglia and encompasses a specific subcortical conflict-dependent component. © 2010 Psychology Press.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results